Will Opdivo and Opdivo Qvantig Drive BMY's Top-Line Growth?

Key Takeaways Bristol Myers' Opdivo growth is fueled by new launches, label expansions, and solid global uptake.EC approved subcutaneous Opdivo and Opdivo Qvantig, boosting momentum across multiple tumor types.BMY trades at 7.60x forward earnings, below industry peers, as EPS estimates trend upward for 2025-2026.Bristol Myers ((BMY) has a strong oncology portfolio comprising blockbuster immune-oncology drug Opdivo, Opdivo Qvantig, and Yervoy, among others.Opdivo is a key drug in BMY’s Growth Portfolio that ...